Drugs / Cecolin
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07377656 | Apr 2026 → Feb 2028 expected | — | International Vaccine Institute | Recruiting | No outcome recorded |
| Phase 32 trials · 2 met primary | ||||||
| Phase 3 | NCT04508309 | Mar 2021 → Dec 2023 | cervical cancer | PATH | Completed | Met primary |
| Phase 3 | NCT01735006 | Nov 2012 → Aug 2019 | cervical cancer, cervical intraepithelial neoplasia, intraepithelial neoplasia, vulvar intraepithelial neoplasia | Xiamen University | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT06345885 | Feb 2023 → Jan 2024 | — | Xiamen Innovax Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT05415345 | Oct 2021 → Nov 2022 | hepatitis E virus infection, human papilloma virus infection | Xiamen Innovax Biotech Co., Ltd | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04537156 Comparator | Sep 2020 → Dec 2027 expected | anogenital human papillomavirus infection, cervical cancer, cervical intraepithelial neoplasia | Xiamen University | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-26 | Xiamen Innovax Biotech Co., Ltd | Results 2024IPVC圆满落幕，Cecolin®闪耀国际舞台！ innovax.cn ↗
这些成果验证了Cecolin®在预防人乳头瘤病毒感染方面的良好效果，得到国际同行的广泛关注和肯定。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-26 | Xiamen Innovax Biotech Co., Ltd | 2024IPVC圆满落幕，Cecolin®闪耀国际舞台！ innovax.cn ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cecolin | “BACKGROUND: Cecolin, a bivalent human papillomavirus (2vHPV) vaccine produced with Escherichia coli, has demonstrated safety and efficacy and is now widely used globally.” PMID 42379209 ↗ Jun 20265“Immunogenicity and Safety of One Dose of Cecolin and One Dose of Gardasil” NCT06345885 ↗ “clinical trial of Cecolin® (ClinicalTrials.gov, NCT01735006)” PMID 41407728 ↗ Dec 2025 “The bivalent Cecolin HPV vaccine” NCT07377656 ↗ |
| Known as | 2vHPV vaccine | “BACKGROUND: Cecolin, a bivalent human papillomavirus (2vHPV) vaccine produced with Escherichia coli, has demonstrated safety and efficacy and is now widely used globally.” PMID 42379209 ↗ Jun 2026 |
| Modality | Vaccine | “bivalent HPV 16 and 18 vaccine” PMID 36037823 ↗ Aug 2022 |
| Route | Intramuscular | “0.5 mL HPV Vaccine Injection Intramuscular” NCT07377656 ↗ |